CN Patent

CN118632695A — 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果

Assigned to Janssen Pharmaceutica NV · Expires 2024-09-10 · 2y expired

What this patent protects

本公开涉及尼拉帕尼和醋酸阿比特龙，加上泼尼松或泼尼松龙；用于在改善具有DNA修复异常的患者的转移性去势抵抗性前列腺癌(mCRPC)的治疗功效的方法中使用，特别是用于改善中位放射影像学无进展生存(rPFS)。

USPTO Abstract

本公开涉及尼拉帕尼和醋酸阿比特龙，加上泼尼松或泼尼松龙；用于在改善具有DNA修复异常的患者的转移性去势抵抗性前列腺癌(mCRPC)的治疗功效的方法中使用，特别是用于改善中位放射影像学无进展生存(rPFS)。

Drugs covered by this patent

Patent Metadata

Patent number
CN118632695A
Jurisdiction
CN
Classification
—
Expires
2024-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.